Clinical The main focus of the post is to support and develop the non-malignant service including laboratory, consultative as well as malignant haematologyNon-malignant haematology: Responsibility for patients with non-malignant haematological disorders including rare inherited anaemias. This includes the regional Specialist Haemoglobinopathy Team service in conjunction with the Regional Haemoglobinopathy Coordinating Centres in Manchester, for Thalassaemia, and Sheffield, for Haemoglobinopathies. Malignant haematology Clinical care of patients treated at the Primary Treatment Centre at GNCH. This would primarily involve the lymphoblastic leukaemia patients however there may be opportunities patient groups depending on expertise and experience. The management of lymphoma, myeloid leukaemias and relapsed leukaemias come under specific teams currently Laboratory and consultative haematology duties: Suitably qualified (FRCPath or equivalent) individuals would be expected to contribute to the paediatric haematology laboratory service. This includes support of biomedical scientist staff across the core haematology laboratory and reporting referred paediatric blood films and the reporting of bone marrow aspirates and CSF cytospin slides Bone marrow trephines are reported by the regional SIHMDS (NEHODS). The post-holder will be encouraged to develop specific areas of responsibility within the laboratory. The post holder will be expected to contribute to the liaison haematology with secondary and tertiary services across the regional subspecialties and general paediatrics. Bone Marrow Transplant: Depending on areas of interest, there may be an opportunity for pre and post transplant care of patients with haematological disorders treated within GNCH. These patients are managed by the Stem Cell Transplant team. Advanced Cellular Therapies: The Great North Childrens Hospital is one of the 3 UK centres Commissioned for CAR-T therapies for children and young people (up to 18 years of age). As well as licensed products, we have an early phase trail products available and be well positioned to develop CAR-T and other cellular therapies for other indications in the future. Please read the Job Description and Person Specification for further information.